Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
141
resultados
Última actualización
14/03/2025 [06:59:00]
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2025084480A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: US2025084174A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Resumen de: WO2024008796A1
The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.
Resumen de: US2025069692A1
The invention is related to a system for treating irritable bowel syndrome, Crohn's disease, ulcerative colitis (collectively, inflammatory bowel disease, or “IBD”) by determining a number of indicators, including genetic markers, gene expression levels, levels of certain compounds in the gut or feces, hydrogen and/or methane levels, and concentrations of particular bacteria in the gut or feces, and correlating one or more such indicators with symptoms in test subjects with IBD; and correlating diet, drugs, supplements or other therapy, with alleviation of IBD symptoms. The correlations established in the test subjects are confirmed or refuted for individuals suffering IBD, and the treatments established as reducing symptoms are supported through messaging and compliance is verified by monitoring the indicators.
Resumen de: AU2023257366A1
The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.
Resumen de: US2025057842A1
Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.
Resumen de: US2025059605A1
The present invention relates to methods of prognosing responsiveness to anti-TNFα therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNFα therapy in an individual diagnosed with IBD.
Resumen de: WO2025038942A1
Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.
Resumen de: WO2023201243A1
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Resumen de: WO2025024629A2
Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.
Resumen de: US2025034613A1
Provided herein are engineered bacterial biosensors and methods of use thereof for detection of gastrointestinal disease, including inflammatory bowel disease.
Resumen de: US2025020667A1
Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.
Resumen de: US2025020660A1
The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
Resumen de: WO2025008439A1
The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.
Resumen de: EP4487864A1
The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and/or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.
Resumen de: WO2025003436A1
The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.
Resumen de: CN119220678A
The invention relates to the technical field of biology, in particular to a kit related to colitis and proctitis malignant transformation, which comprises an intelligent system and a top cover, a semiconductor chilling plate is arranged at the bottom of the top cover, and a cooling fin is arranged at the top of the top cover; one side of the top cover is rotationally connected with a box body; a plurality of partition plates are fixedly connected into the box body and divide the interior of the box body into a plurality of containing cavities, and fixing assemblies are arranged on the side walls of the containing cavities. The miRNA marker related to the malignant transformation of colitis and proctitis comprises a miRNA marker body, and the miRNA marker body is one or more of miR-138-5p, miR-145-5p, miR-146a-5p, miR-150-5p, miR-146a, miR-27a, miR-29a, miR-20a and miR-21. The miRNA marker can be used for detecting the malignant transformation of colitis and proctitis. A detection agent is fixed through an elastic stretching plate and a magnet, so that the possibility that the detection agent is damaged is reduced; the interior of the kit is cooled through a semiconductor chilling plate, so that a detection agent and a detection plate can be stored for a long time; high-throughput detection of the miRNA marker is realized through the detection plate, and the detection efficiency is improved.
Resumen de: CN119223942A
本发明公开了一种磁性水凝胶包裹细菌生物传感器平台与应用，属于合成生物学及临床诊断领域。该水凝胶递送回收体系包括水凝胶包裹的全细胞生物传感器和磁性微粒，其中，所述水凝胶由海藻酸钠和氯化钙构建，所述生物传感器为感应血红素的细菌。更具体地，本发明是使用海藻酸钠水凝胶封装工程细菌YES601和磁性Fe3O4微粒形成磁性水凝胶微球，作为生物传感器递送至肠道可以感应血红素而发光，再通过磁性吸附的方式从粪便中高效回收完整微球进行检测，提高了全细胞生物传感器检测肠道出血效率以及安全性。本发明提供的水凝胶递送回收体系整体设计优化策略可以提高诊断效率和实际应用价值。
Resumen de: US2024425923A1
Described herein are systems and methods for stratifying intestinal mononuclear phagocytes (MNP) expression profiles in subjects with an inflammatory bowel disease (IBD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.
Resumen de: FI20225151A1
The present invention is related to a method for determining or confirming chronic inflammatory intestinal disease or a risk thereof in a subject. The method comprises detecting the presence of keratin 7 (K7) mRNA or protein in a biological sample obtained from a subject.
Resumen de: CN119183380A
The present disclosure relates to: a method for treating IBD using digestive tract content or excreta modified with an IgA antibody, a composition, and a method for producing the same; a method for obtaining an IgA antibody that makes the flora in the digestive tract of an IBD patient sound; methods, compositions, and methods of making the same for modifying the contents or excreta of the digestive tract of an IBD patient using an IgA antibody; a method for testing a patient treated with an IBD therapeutic agent containing digestive tract contents or excreta using a diagnostic agent containing an IgA antibody; a composition; and a method for producing the composition.
Resumen de: CN119162304A
The invention discloses a Crohn disease enteric microorganism marker and application thereof and a method for constructing a Crohn disease detection model.The Crohn disease enteric microorganism marker is characterized in that enteric microorganisms related to Crohn disease are extracted from metagenome data of samples of Crohn disease patients and healthy people; the method comprises the following steps: establishing a random forest model for diagnosing the Crohn disease through the intestinal microbial marker of the Crohn disease, and evaluating to obtain a Crohn disease detection model; according to the method provided by the invention, the treatment effect can be evaluated, the treatment scheme can be adjusted in time, and a new tool is provided for prognosis evaluation of a patient; the specific intestinal microbial marker aiming at the Crohn's disease is found and applied, so that the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of the Crohn's disease are improved, the understanding of the Crohn's disease is deepened, and the development of microbiomics in clinical application is promoted; new biomarkers can be found easily, and new biomarkers or therapeutic targets can be found.
Resumen de: KR20240175341A
본 발명은 ATP의 검출능을 갖는 효모, ATP의 검출방법 및 ATP의 검출방법에 의한 염증성 장 질환 진단용 바이오마커에 관한 것으로, 본 발명의 반딧불이 루시페라제를 발현하는 재조합 효모를 기반으로 하는 ATP의 검출방법인 전세포 기반 센서 시스템을 활용하여 ATP를 쉽게 검출할 수 있고 이를 이용하여 비침습 적으로 염증성 장 질환(IBD)과 같은 ATP 관련 질병의 진단에 유용하게 활용할 수 있다.
Nº publicación: WO2024256789A1 19/12/2024
Solicitante:
UNIV DE FRANCHE COMTE [FR]
UNIVERSITE DE FRANCHE COMTE
Resumen de: WO2024256789A1
The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg/ml and interleukin 8 (IL-8) at a concentration of more than 150 pg/ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg/ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg/ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
BOPI
Sede Electrónica
